InterMune Gets Europe Approval Backing For Lung Drug
NEW YORK -(Dow Jones)- InterMune Inc. (ITMN) obtained a key recommendation that should lead to European approval of its drug Esbriet for the fatal lung disease called idiopathic pulmonary fibrosis, news that more than...